Previously, we have screened growth inhibition activities of arylsulfonamide compounds designed as Stat3 inhibitors against pancreatic cancer cell lines12, as Stat3 activation is important for cancer progression3. This evidence concerns the gene STAT3 and pancreatic neoplasm.